Vivos Therapeutics Valuation and Analyst Outlook Vivos Therapeutics (NasdaqCM: VVOS) faces a recalibrated valuation as analysts adjust price targets amid concerns over the company’s balance sheet. Alliance Global recently lowered its price target for Vivos Therapeutics to US$0.75 from US$1.75, maintaining a Neutral rating. This adjustment reflects heightened financial risk and the potential for equity … Read more
Alvotech has secured US$240 million in combined liquidity to stabilize its operations and fund its biosimilar pipeline, following a US$165 million equity raise in June 2026 and a new US$75 million term loan facility led by GoldenTree Asset Management. This capital infusion aims to address near-term liquidity constraints while supporting product launches and global expansion … Read more
The Fortress Balance Sheet: Why Zero Debt is the Ultimate Dividend Safeguard In an era of fluctuating interest rates and unpredictable global markets, investors are increasingly hunting for one specific trait: certainty. When a company’s board decides to raise dividends, it isn’t just a gesture of goodwill; it is a signal of financial health. But … Read more